Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

NeuroTherapeutics Pharma

Request full access

NeuroTherapeutics Pharma develops therapeutics for patients suffering from central nervous system disorders

Chicago Heights, United StatesFounded 2006Biotech & Life Sciences

About NeuroTherapeutics Pharma

NeuroTherapeutics Pharma (NTP) was a biopharmaceutical firm established in 2006, headquartered in Chicago, with a clear focus on the development of novel treatments for central nervous system (CNS) disorders. The company's strategic direction was shaped by a management team with considerable experience in CNS drug development, including key executives who previously held positions at Ovation Pharmaceuticals. This team collectively had a track record of filing over 15 Investigational New Drug (IND) applications and securing approval for eight New Drug Applications (NDAs).

The company's core business was centered on discovering and advancing a pipeline of proprietary molecules for conditions such as epilepsy, as well as neuropathic and acute pain. NTP's operational model involved conducting preclinical studies and advancing its lead compounds toward human clinical trials, with the ultimate goal of commercialization. The business strategy relied on securing funding from venture capital and strategic investors to finance these long and capital-intensive research and development cycles. NTP successfully raised a total of $55 million over three funding rounds, including a significant $43 million Series B in 2010 and a $12 million Series C in 2011. Key investors included prominent names such as SR One, MPM Capital, F-Prime Capital (Fidelity Biosciences), Novo Ventures, and Pfizer, among others.

NTP's primary asset was its lead compound, NTP-2014, which demonstrated promising efficacy in various preclinical models for epilepsy and pain. The compound was designed to work through a new mechanism of action, distinct from other marketed products, by targeting a novel molecular site to reduce aberrant excitatory discharges in the nervous system. Preclinical data suggested a favorable safety profile and superior performance compared to existing blockbuster drugs at the time. The plan was to advance NTP-2014 through multiple Phase II proof-of-concept trials. Despite its promising technology and substantial financial backing, NeuroTherapeutics Pharma eventually ceased operations and is now considered a deadpooled company.

Source: Dealroom company data

At a glance

Status
Closed
Employees
1
Open positions
None listed
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VCOther financing Dec 2011 $12M $48M Pfizer Ventures —
SERIES BOther financing May 2010 $43M $172M GSK · F-Prime · SR One · MPM BioImpact —
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

NeuroTherapeutics Pharma website traffic

Latest recorded traffic for NeuroTherapeutics Pharma is 0 monthly website visits, down 100% over the last three months. NeuroTherapeutics Pharma's team grew 0% over the past year.

Latest monthly visits0 3-month web change-100% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

NeuroTherapeutics Pharma in the Chicago Heights ecosystem

Live from Dealroom

The NeuroTherapeutics Pharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

  • SR One
  • MPM BioImpact
  • GSK
  • F-Prime
  • Novo Ventures

Series B and later1 investor entered at this stage

  • Pfizer Ventures
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Chicago Heights HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about NeuroTherapeutics Pharma on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See NeuroTherapeutics Pharma’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.